Browse by Series:

Race/Ethnicity and Clinical Outcomes in Breast Cancer

Insights From: Joseph A. Sparano, MD, Albert Einstein College of Medicine
Published: Wednesday, Jan 02, 2019



Transcript:

Joseph A. Sparano, MD: There was a very interesting presentation by Dr. Kathy Albain, one of the co-investigators of the TAILORx trial, that focused on the impact of race and ethnicity on clinical outcomes. And there were several really important conclusions that came from this. First of all, about 8% of the patients who enrolled in the trial were African American, and somewhere in the order of 12% or so were of Hispanic ethnicity. When we looked at the clinical characteristics of the black or Hispanic patients versus nonblack or white patients, and Hispanic versus non-Hispanic populations, the clinical characteristics were largely similar
SELECTED
LANGUAGE
Slider Left
Slider Right


Transcript:

Joseph A. Sparano, MD: There was a very interesting presentation by Dr. Kathy Albain, one of the co-investigators of the TAILORx trial, that focused on the impact of race and ethnicity on clinical outcomes. And there were several really important conclusions that came from this. First of all, about 8% of the patients who enrolled in the trial were African American, and somewhere in the order of 12% or so were of Hispanic ethnicity. When we looked at the clinical characteristics of the black or Hispanic patients versus nonblack or white patients, and Hispanic versus non-Hispanic populations, the clinical characteristics were largely similar
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: How Do We Leverage PARP Inhibition Strategies in the Contemporary Treatment of Breast Cancer?May 31, 20191.5
Community Practice Connections™: A Better Way to Stop Pain: Paths Toward Responsible Postsurgical Pain Management for Patients With Breast CancerMay 31, 20191.5
Publication Bottom Border
Border Publication
x